KBI Biopharma is a Contract Development and Manufacturing Organization (CDMO) that specializes in accelerating the development of innovative biological products. The company serves a diverse range of clients, including early-stage biotech firms, global pharmaceutical companies, and academic non-profit organizations. KBI Biopharma operates in the biopharmaceutical market, focusing on transforming scientific discoveries into life-changing medicines. The business model is centered around providing rapid cell line generation services using established mammalian and microbial recombinant protein expression systems, such as CHO K1, CHO S, CHO DG44, HEK293, and DXB11 E. coli. These services are designed to meet the timeline and budgetary objectives of preclinical programs. KBI Biopharma generates revenue through its comprehensive suite of development and manufacturing services, which include both standalone cell line development and fully integrated process development programs. The company aims to reduce risk and build value for its clients while expanding global access to essential medicines.

Keywords: CDMO, biopharma, cell line development, mammalian systems, microbial systems, recombinant protein, preclinical programs, biotech, pharmaceutical, innovation.